Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial.
暂无分享,去创建一个
B. Mellado | E. Esteban | A. Font | I. Durán | D. Castellano | M. Quintela | P. Maroto | M. Duran | J. Puente | J. Cassinello | A. G. D. Alba | J. A. Arija | C. Santander | M. Vidal | B. Valderrama | M. Fita | T. A. Gordoa | A. Sánchez-Hernandez | M. Sáez